pISSN 1226-6051
eISSN 2508-786X

Table. 4.

Table. 4.

Appropriateness of clarity, acceptability, and applicability for guideline contents

All respondents (n=94)aWork sitesWork departments

Clinical trial centers (n=21)Pharmaceutical Companies (n=51)Clinical research organizations (n=11)Clinical trial management (n=18)Approval and registration (n=45)Research and Development (n=20)
Clarityb3.67±0.634.00±0.45f3.61±0.703.64±0.513.94±0.643.64±0.533.65±0.81
 Appropriatec91 (96.8%)21 (100%)48 (94.1%)11 (100%)18 (100%)44 (97.8%)18 (90.0%)
 Goodd61 (64.9%)19 (90.5%)31 (60.8%)7 (63.6%)14 (77.8%)30 (66.7%)13 (65.0%)
Acceptabilityb4.09±0.46e4.19±0.754.06±0.654.00±1.004.17±0.794.20±0.633.75±0.79
 Appropriate91 (96.8%)20 (95.2%)50 (98.0%)10 (90.9%)17 (94.4%)45 (100%)18 (90.0%)
 Good79 (84.0%)19 (90.5%)44 (86.3%)8 (72.7%)16 (88.9%)40 (88.9%)15 (65.0%)
Applicabilityb3.52±0.683.86±0.573.49±0.673.36±0.813.61±0.703.58±0.723.50±0.61
 Appropriate88 (93.6%)20 (95.2%)49 (96.1%)9 (81.8%)17 (94.4%)41 (91.1%)20 (100%)
 Good51 (54.3%)18 (85.7%)24 (47.1%)6 (54.5%)11 (61.1%)28 (62.2%)9 (45.0%)

The demographic table contains the information about 83 respondents because 11 people skipped answering the personal information

The results are given as mean±SD

The criteria appropriate is defined with the score of 3-point or more and given as N (%).

The criteria good is defined with the score of 4-point or more and given as N (%).

The total acceptability score was different from other scores by a Kruskal Wallis test (p<0.05).

The scores of Clinical Trial Centers were significantly different from those of Pharmaceutical Companies by a post hoc Bonferroni corrected Mann-Whitney U-test (p<0.05).

Korean J Clin Pharm 2019;29:267-77 https://doi.org/10.24304/kjcp.2019.29.4.267
© 2019 Korean J Clin Pharm